LP533401 restores bone health in 5/6 nephrectomized rats by a decrease of gut-derived serotonin and regulation of serum phosphate through the inhibition of phosphate co-transporters expression in the kidneys
Abstract
No abstract availableKeywords
Funding Information
- National Science Centre (2013/09/B/NZ7/00046, N/ST/ZB/17/002/2228, N/ST/ZB/17/003/2228)
- Medical University of Bialystok
This publication has 43 references indexed in Scilit:
- Pharmaceutical Excipients Influence the Function of Human Uptake Transporting ProteinsMolecular Pharmaceutics, 2012
- Decreased osteoclastogenesis in serotonin-deficient miceProceedings of the National Academy of Sciences, 2012
- The role of vitamin D in the FGF23, klotho, and phosphate bone-kidney endocrine axisReviews in Endocrine and Metabolic Disorders, 2011
- Efficacy of serotonin inhibition in mouse models of bone lossJournal of Bone and Mineral Research, 2011
- Lrp5 functions in bone to regulate bone massNature Medicine, 2011
- Minireview: A Skeleton in Serotonin’s Closet?Endocrinology, 2010
- Pharmacological inhibition of gut-derived serotonin synthesis is a potential bone anabolic treatment for osteoporosisNature Medicine, 2010
- The emerging role of serotonin (5-hydroxytryptamine) in the skeleton and its mediation of the skeletal effects of low-density lipoprotein receptor-related protein 5 (LRP5)Bone, 2010
- A Serotonin-Dependent Mechanism Explains the Leptin Regulation of Bone Mass, Appetite, and Energy ExpenditureCell, 2009
- Lrp5 Controls Bone Formation by Inhibiting Serotonin Synthesis in the DuodenumCell, 2008